| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 13559* | 2021 |
| Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial A Grothey, E Van Cutsem, A Sobrero, S Siena, A Falcone, M Ychou, ... The Lancet 381 (9863), 303-312, 2013 | 3225 | 2013 |
| Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study MJ Overman, R McDermott, JL Leach, S Lonardi, HJ Lenz, MA Morse, ... The lancet oncology 18 (9), 1182-1191, 2017 | 2746 | 2017 |
| Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer MJ Overman, S Lonardi, KYM Wong, HJ Lenz, F Gelsomino, M Aglietta, ... Journal of clinical oncology 36 (8), 773-779, 2018 | 2042 | 2018 |
| Randomized trial of TAS-102 for refractory metastatic colorectal cancer RJ Mayer, E Van Cutsem, A Falcone, T Yoshino, R Garcia-Carbonero, ... New England Journal of Medicine 372 (20), 1909-1919, 2015 | 1502 | 2015 |
| EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer AF Sobrero, J Maurel, L Fehrenbacher, W Scheithauer, YA Abubakr, ... Journal of clinical oncology 26 (14), 2311-2319, 2008 | 1212 | 2008 |
| CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation–a target for novel cancer therapy R Tokunaga, WU Zhang, M Naseem, A Puccini, MD Berger, S Soni, ... Cancer treatment reviews 63, 40-47, 2018 | 1175 | 2018 |
| Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase D Salonga, KD Danenberg, M Johnson, R Metzger, S Groshen, ... Clinical Cancer Research 6 (4), 1322-1327, 2000 | 1123 | 2000 |
| Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer E Van Cutsem, HJ Lenz, CH Köhne, V Heinemann, S Tejpar, I Melezínek, ... Journal of clinical oncology 33 (7), 692-700, 2015 | 939 | 2015 |
| Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six … D Arnold, B Lueza, JY Douillard, M Peeters, HJ Lenz, A Venook, ... Annals of oncology 28 (8), 1713-1729, 2017 | 916 | 2017 |
| Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors PG Johnston, HJ Lenz, CG Leichman, KD Danenberg, CJ Allegra, ... Cancer research 55 (7), 1407-1412, 1995 | 904 | 1995 |
| Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a … AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, B Fruth, JA Meyerhardt, ... Jama 317 (23), 2392-2401, 2017 | 872 | 2017 |
| ERCC1 and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy Y Shirota, J Stoehlmacher, J Brabender, YP Xiong, H Uetake, ... Journal of Clinical Oncology 19 (23), 4298-4304, 2001 | 856 | 2001 |
| Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials S Tejpar, S Stintzing, F Ciardiello, J Tabernero, E Van Cutsem, F Beier, ... JAMA oncology 3 (2), 194-201, 2017 | 805 | 2017 |
| The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer MM Pomerantz, N Ahmadiyeh, LI Jia, P Herman, MP Verzi, ... Nature genetics 41 (8), 882-884, 2009 | 798 | 2009 |
| Activity of sunitinib in patients with advanced neuroendocrine tumors MH Kulke, HJ Lenz, NJ Meropol, J Posey, DP Ryan, J Picus, E Bergsland, ... Journal of Clinical Oncology 26 (20), 3403-3410, 2008 | 765 | 2008 |
| Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy ST Pullarkat, J Stoehlmacher, V Ghaderi, YP Xiong, SA Ingles, A Sherrod, ... The pharmacogenomics journal 1 (1), 65-70, 2001 | 733 | 2001 |
| ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil … R Metzger, CG Leichman, KD Danenberg, PV Danenberg, HJ Lenz, ... Journal of Clinical Oncology 16 (1), 309-316, 1998 | 689 | 1998 |
| Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret … AA Garcia, H Hirte, G Fleming, D Yang, DD Tsao-Wei, L Roman, ... Journal of Clinical Oncology 26 (1), 76-82, 2008 | 687 | 2008 |
| Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124 PN Lara Jr, R Natale, J Crowley, HJ Lenz, MW Redman, JE Carleton, ... Journal of clinical oncology 27 (15), 2530-2535, 2009 | 644 | 2009 |
WU ZHANGUniversity of Southern California/Norris Cancer CenterEmail verificata su usc.edu